Macular Degeneration Treatment Market
Industry: Healthcare
Published Date: October-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33174
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Development and Innovation Trends
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Recent Product Launches and Approvals
4.3. Strategic Promotional Strategies
4.4. Disease Epidemiology
4.5. Regulatory and Reimbursement Scenario
4.6. Product Pipeline Assessment
4.7. Porters Analysis
4.8. PESTLE Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Alternative Treatment Market Growth
5.2.2. Technological Advances
5.2.3. Development of Novel Products
5.2.4. Regulatory Imposition
5.2.5. Product Pipeline
5.2.6. Per Patient Spending
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis – Impact Assessment
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug
6.1.2. Revenue By Route of Administration
6.1.3. Revenue By Indication
6.1.4. Revenue By End User
6.1.5. Revenue By Country
6.2. 2021 Market Scenario
7. Global Macular Degeneration Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2012–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2022–2032
8.3.1. Anti-vascular Endothelial Growth Factor
8.3.2. Other
8.4. Market Attractiveness Analysis By Drug
9. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022–2032
9.3.1. Intravenous Route
9.3.2. Intravitreal Route
9.3.3. Others
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2012–2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032
10.3.1. Dry Age-related Macular Degeneration
10.3.2. Wet Age-related Macular Degeneration
10.4. Market Attractiveness Analysis By Indication
11. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2012–2021
11.3. Current and Future Market Size (US$ Mn) and Forecast By End User, 2022–2032
11.3.1. Hospitals
11.3.2. Ophthalmology Clinics
11.3.3. Ambulatory Surgical Centers
11.3.4. Others
11.4. Market Attractiveness Analysis By End User
12. Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. The Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
13.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug
13.3.3. By Route of Administration
13.3.4. By Indication
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Route of Administration
13.4.4. By Indication
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Macular Degeneration Treatment Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug
13.8.1.2.2. By Route of Administration
13.8.1.2.3. By Indication
13.8.1.2.4. By End User
13.8.2. Canada Macular Degeneration Treatment Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug
13.8.2.2.2. By Route of Administration
13.8.2.2.3. By Indication
13.8.2.2.4. By End User
14. Latin America Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
14.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug
14.3.3. By Route of Administration
14.3.4. By Indication
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Route of Administration
14.4.4. By Indication
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Macular Degeneration Treatment Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Route of Administration
14.8.1.2.3. By Indication
14.8.1.2.4. By End User
14.8.2. Mexico Macular Degeneration Treatment Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Route of Administration
14.8.2.2.3. By Indication
14.8.2.2.4. By End User
14.8.3. Argentina Macular Degeneration Treatment Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Route of Administration
14.8.3.2.3. By Indication
14.8.3.2.4. By End User
15. Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
15.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug
15.3.3. By Route of Administration
15.3.4. By Indication
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Route of Administration
15.4.4. By Indication
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Macular Degeneration Treatment Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Route of Administration
15.8.1.2.3. By Indication
15.8.1.2.4. By End User
15.8.2. Italy Macular Degeneration Treatment Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Route of Administration
15.8.2.2.3. By Indication
15.8.2.2.4. By End User
15.8.3. France Macular Degeneration Treatment Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Route of Administration
15.8.3.2.3. By Indication
15.8.3.2.4. By End User
15.8.4. U.K. Macular Degeneration Treatment Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug
15.8.4.2.2. By Route of Administration
15.8.4.2.3. By Indication
15.8.4.2.4. By End User
15.8.5. Spain Macular Degeneration Treatment Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug
15.8.5.2.2. By Route of Administration
15.8.5.2.3. By Indication
15.8.5.2.4. By End User
15.8.6. BENELUX Macular Degeneration Treatment Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug
15.8.6.2.2. By Route of Administration
15.8.6.2.3. By Indication
15.8.6.2.4. By End User
15.8.7. Russia Macular Degeneration Treatment Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug
15.8.7.2.2. By Route of Administration
15.8.7.2.3. By Indication
15.8.7.2.4. By End User
16. South Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
16.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Drug
16.3.3. By Route of Administration
16.3.4. By Indication
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Route of Administration
16.4.4. By Indication
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Macular Degeneration Treatment Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Route of Administration
16.8.1.2.3. By Indication
16.8.1.2.4. By End User
16.8.2. Indonesia Macular Degeneration Treatment Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Route of Administration
16.8.2.2.3. By Indication
16.8.2.2.4. By End User
16.8.3. Malaysia Macular Degeneration Treatment Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Route of Administration
16.8.3.2.3. By Indication
16.8.3.2.4. By End User
16.8.4. Thailand Macular Degeneration Treatment Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug
16.8.4.2.2. By Route of Administration
16.8.4.2.3. By Indication
16.8.4.2.4. By End User
17. East Asia Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
17.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Drug
17.3.3. By Route of Administration
17.3.4. By Indication
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Route of Administration
17.4.4. By Indication
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Macular Degeneration Treatment Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug
17.8.1.2.2. By Route of Administration
17.8.1.2.3. By Indication
17.8.1.2.4. By End User
17.8.2. Japan Macular Degeneration Treatment Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug
17.8.2.2.2. By Route of Administration
17.8.2.2.3. By Indication
17.8.2.2.4. By End User
17.8.3. South Korea Macular Degeneration Treatment Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug
17.8.3.2.2. By Route of Administration
17.8.3.2.3. By Indication
17.8.3.2.4. By End User
18. Oceania Macular Degeneration Treatment Market 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
18.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug
18.3.3. By Route of Administration
18.3.4. By Indication
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Route of Administration
18.4.4. By Indication
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Macular Degeneration Treatment Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Route of Administration
18.8.1.2.3. By Indication
18.8.1.2.4. By End User
18.8.2. New Zealand Macular Degeneration Treatment Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Route of Administration
18.8.2.2.3. By Indication
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012–2021
19.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032
19.3.1. By Country
19.3.1.1. Turkey
19.3.1.2. GCC Countries
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug
19.3.3. By Route of Administration
19.3.4. By Indication
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug
19.4.3. By Route of Administration
19.4.4. By Indication
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. Turkey Macular Degeneration Treatment Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug
19.8.1.2.2. By Route of Administration
19.8.1.2.3. By Indication
19.8.1.2.4. By End User
19.8.2. GCC Countries Macular Degeneration Treatment Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug
19.8.2.2.2. By Route of Administration
19.8.2.2.3. By Indication
19.8.2.2.4. By End User
19.8.3. South Africa Macular Degeneration Treatment Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug
19.8.3.2.2. By Route of Administration
19.8.3.2.3. By Indication
19.8.3.2.4. By End User
19.8.4. North Africa Macular Degeneration Treatment Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug
19.8.4.2.2. By Route of Administration
19.8.4.2.3. By Indication
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis (%) of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Product footprint by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive (Tentative List)
21.3.1. F. Hoffmann-La Roche Ltd.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Key Financials
21.3.1.4. Sales Footprint
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.2. Novartis AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Key Financials
21.3.2.4. Sales Footprint
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.3. Bayer AG
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Key Financials
21.3.3.4. Sales Footprint
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.4. Pfizer Inc.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Key Financials
21.3.4.4. Sales Footprint
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.5. Bausch Health Companies Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Key Financials
21.3.5.4. Sales Footprint
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.6. Regeneron Pharmaceuticals Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Key Financials
21.3.6.4. Sales Footprint
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.7. Amgen Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Key Financials
21.3.7.4. Sales Footprint
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.8. Biogen
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Key Financials
21.3.8.4. Sales Footprint
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.9. Samsung Bioepis
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Key Financials
21.3.9.4. Sales Footprint
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.10. Santen Pharmaceutical Co., Ltd.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Key Financials
21.3.10.4. Sales Footprint
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 02: Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 03: Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 04: Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 05: Global Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Region
Table 06: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 07: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 08: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 09: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 10: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 11: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 12: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 13: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 14: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 15: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 16: Europe Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 17: Europe Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 18: Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 19: Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 20: Europe Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 21: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 22: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 23: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 24: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 25: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 26: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 27: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 28: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 29: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 30: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 31: Oceania Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 32: Oceania Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 33: Oceania Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 34: Oceania Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 35: Oceania Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by End User
Table 36: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Country
Table 37: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Analysis 2012–2021 and Forecast 2022–2032, by Drug
Table 38: Middle East & Africa Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Route of administration
Table 39: Middle East & Africa Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by Indication
Table 40: Middle East & Africa Macular Degeneration Treatment Market Analysis 2012–2021 and Forecast 2022–2032, by End User
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 02: Global Macular Degeneration Treatment Market Forecast & Y-o-Y Growth, 2022–2032
Figure 03: Global Macular Degeneration Treatment Market Absolute $ Opportunity (US$ Mn) Analysis, 2021–2032
Figure 04: Global Macular Degeneration Treatment Market Value Share (%) Analysis 2022 and 2032, by Drug
Figure 05: Global Macular Degeneration Treatment Market Y-o-Y Growth (%) Analysis 2021-2032, by Drug
Figure 06: Global Macular Degeneration Treatment Market Attractiveness Analysis 2022–2032, by Drug
Figure 07: Global Macular Degeneration Treatment Market Value Share (%) Analysis 2022 and 2032, by Route of administration
Figure 08: Global Macular Degeneration Treatment Market Y-o-Y Growth (%) Analysis 2021-2032, by Route of administration
Figure 09: Global Macular Degeneration Treatment Market Attractiveness Analysis 2022–2032, by Route of administration
Figure 10: Global Macular Degeneration Treatment Market Value Share (%) Analysis 2022 and 2032, by Indication
Figure 11: Global Macular Degeneration Treatment Market Y-o-Y Growth (%) Analysis 2021-2032, by Indication
Figure 12: Global Macular Degeneration Treatment Market Attractiveness Analysis 2022–2032, by Indication
Figure 13: Global Macular Degeneration Treatment Market Value Share (%) Analysis 2022 and 2032, by End User
Figure 14: Global Macular Degeneration Treatment Market Y-o-Y Growth (%) Analysis 2021-2032, by End User
Figure 15: Global Macular Degeneration Treatment Market Attractiveness Analysis 2022–2032, by End User
Figure 16: Global Macular Degeneration Treatment Market Value Share (%) Analysis 2022 and 2032, by Region
Figure 17: Global Macular Degeneration Treatment Market Y-o-Y Growth (%) Analysis 2021-2032, by Region
Figure 18: Global Macular Degeneration Treatment Market Attractiveness Analysis 2022–2032, by Region
Figure 19: North America Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 20: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 21: North America Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 22: North America Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 23: North America Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 24: North America Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 25: North America Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 26: North America Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 27: North America Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 28: North America Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 29: North America Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 30: North America Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 31: U.S. Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 32: Global Vs. U.S. Growth Comparison
Figure 33: U.S. Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 34: U.S. Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 35: U.S. Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 36: U.S. Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 37: Canada Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 40: Canada Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 41: Canada Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 42: Canada Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 43: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 44: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 45: Latin America Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 46: Latin America Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 47: Latin America Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 48: Latin America Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 49: Latin America Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 50: Latin America Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 51: Latin America Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 52: Latin America Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 53: Latin America Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 54: Latin America Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 55: Mexico Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 58: Mexico Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 59: Mexico Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 60: Mexico Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 61: Brazil Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 64: Brazil Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 65: Brazil Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 66: Brazil Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 67: Argentina Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 70: Argentina Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 71: Argentina Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 72: Argentina Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 73: Europe Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 74: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 75: Europe Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 76: Europe Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 77: Europe Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 78: Europe Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 79: Europe Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 80: Europe Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 81: Europe Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 82: Europe Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 83: Europe Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 84: Europe Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 85: UK Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 88: UK Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 89: UK Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 90: UK Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 91: Germany Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 94: Germany Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 95: Germany Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 96: Germany Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 97: Italy Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 100: Italy Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 101: Italy Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 102: Italy Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 103: France Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 104: Global Vs France Growth Comparison
Figure 105: France Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 106: France Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 107: France Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 108: France Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 109: Spain Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 112: Spain Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 113: Spain Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 114: Spain Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 115: Russia Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 118: Russia Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 119: Russia Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 120: Russia Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 121: BENELUX Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 124: BENELUX Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 125: BENELUX Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 126: BENELUX Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 127: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 128: East Asia Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 129: East Asia Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 130: East Asia Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 131: East Asia Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 132: East Asia Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 133: East Asia Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 134: East Asia Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 135: East Asia Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 136: East Asia Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 137: East Asia Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 138: East Asia Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 139: China Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 142: China Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 143: China Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 144: China Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 145: Japan Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 148: Japan Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 149: Japan Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 150: Japan Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 151: South Korea Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 154: South Korea Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 155: South Korea Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 156: South Korea Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 157: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 158: South Asia Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 159: South Asia Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 160: South Asia Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 161: South Asia Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 162: South Asia Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 163: South Asia Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 164: South Asia Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 165: South Asia Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 166: South Asia Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 167: South Asia Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 168: South Asia Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 169: India Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 172: India Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 173: India Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 174: India Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 175: Indonesia Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 178: Indonesia Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 179: Indonesia Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 180: Indonesia Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 181: Malaysia Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 184: Malaysia Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 185: Malaysia Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 186: Malaysia Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 187: Thailand Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 190: Thailand Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 191: Thailand Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 192: Thailand Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 193: Oceania Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 194: Oceania Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 195: Oceania Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 196: Oceania Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 197: Oceania Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 198: Oceania Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 199: Oceania Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 200: Oceania Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 201: Oceania Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 202: Oceania Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 203: Oceania Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 204: Oceania Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 205: Australia Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 208: Australia Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 209: Australia Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 210: Australia Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 211: New Zealand Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 214: New Zealand Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 215: New Zealand Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 216: New Zealand Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 217: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Analysis, 2012–2021
Figure 218: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, 2022-2032
Figure 219: Middle East & Africa Macular Degeneration Treatment Market Value Share, by Drug (2022 E)
Figure 220: Middle East & Africa Macular Degeneration Treatment Market Value Share, by Route of administration (2022 E)
Figure 221: Middle East & Africa Macular Degeneration Treatment Market Value Share, by Indication (2022 E)
Figure 222: Middle East & Africa Macular Degeneration Treatment Market Value Share, by End User (2022 E)
Figure 223: Middle East & Africa Macular Degeneration Treatment Market Value Share, by Country (2022 E)
Figure 224: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis by Drug, 2022–2032
Figure 225: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis by Route of administration, 2022–2032
Figure 226: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis by Indication, 2022–2032
Figure 227: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis by End User, 2022–2032
Figure 228: Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis by Country, 2022–2032
Figure 229: GCC Countries Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 232: GCC Countries Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 233: GCC Countries Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 234: GCC Countries Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 235: Turkey Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 236: Global Vs. Turkey Growth Comparison
Figure 237: Turkey Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 238: Turkey Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 239: Turkey Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 240: Turkey Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 241: South Africa Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 244: South Africa Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 245: South Africa Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 246: South Africa Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
Figure 247: North Africa Macular Degeneration Treatment Market Value Proportion Analysis, 2021
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Macular Degeneration Treatment Market Share Analysis (%) by Drug, 2021 & 2032
Figure 250: North Africa Macular Degeneration Treatment Market Share Analysis (%) by Route of administration, 2021 & 2032
Figure 251: North Africa Macular Degeneration Treatment Market Share Analysis (%) by Indication, 2021 & 2032
Figure 252: North Africa Macular Degeneration Treatment Market Share Analysis (%) by End User, 2021 & 2032
